Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.50 |
| ▸ | HTR2B | P41595 | 6/20 | 0.50 |
| ▸ | HTR2A | P28223 | 6/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.38 |
| ▸ | PGR | P06401 | 6/20 | 0.38 |
| ▸ | AR | P10275 | 6/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6785200 | 0.87 | MAPT (0.46) | HTR2CHTR2BHTR2ACYP3A4MAPT | |
| SCHEMBL6085848 | 0.85 | HTR2A (0.46) | HTR2CHTR2BHTR2ANR3C1PGR | |
| SCHEMBL5366510 | 0.83 | RXRA (0.45) | HTR2CHTR2BHTR2ANR3C1PGR | |
| SCHEMBL1496270 | 0.82 | MAPT (0.38) | HTR2CHTR2BHTR2ACYP3A4MAPT | |
| SCHEMBL1496061 | 0.81 | CYP3A4 (0.40) | HTR2CHTR2BHTR2ACYP3A4MAPT | |
| SCHEMBL10324926 | 0.81 | HTR2A (0.41) | HTR2CHTR2BHTR2ACYP3A4MAPT | |
| SCHEMBL4235784 | 0.81 | BCHE (0.45) | MAPT | |
| SCHEMBL4654263 | 0.79 | RXRA (0.37) | HTR2CHTR2ACYP3A4MAPT | |
| SCHEMBL29151740 | 0.78 | HTR2A (0.46) | HTR2CHTR2BHTR2ANR3C1PGR | |
| SCHEMBL31525583 | 0.78 | PKM (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4511114-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| WO-2023205778-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205778-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| US-9051331-B2 | Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2015-06-09 | — | — | US | disclosed |
| EP-2477994-B1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2013-12-11 | — | — | EP | disclosed |
| EP-2477994-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-20120184566-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI (FR) | 2012-07-19 | — | — | US | disclosed |
| WO-2011034830-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184566-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | GRM2, GRM1, GRIN2C | HTR2C 35/4885HTR2B 75/4885HTR2A 46/4885 |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | HTR2C 178/4885HTR2B 317/4885HTR2A 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.